Medlab Clinical (ASX:MDC) says it has received 'Favourable Opinion' status from the UK Research Ethics Committee for the forthcoming NanaBis Phase 3 trial.
The company previously announced Australian Ethics acceptance and Clinical Trial Notification (CTN).
NanaBis is a patented non-opioid analgesic designed to treat cancer and noncancer bone pain. CEO and managing director, Dr Sean Hall, said, “UK Ethics approval is an important step towards our NanaBis P3 trial and we are very happy with the result. We can now move forward with final UK clinical trials approval, at which point we will announce the UK Hospitals and Principal Investigators.”
The company said the next steps for Medlab in relation to UK Ethics will be Clinical Trial Approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA).
It said it plans to start Phase 3 trials with approximately 120 patients in each of Australia, the UK and the US.